Purpose of this Study
If you choose to join this study, you will get a random assignment to 1 of 2 groups:
- One group will the study drug
- The other group will get a placebo (inactive substance that has no drug in it)
In addition to the study drug or placebo, you will also take either a drug called envafolimab or a combination of envafolimab and doxorubicin. Whether or not you take envafolimab alone or in combination with doxorubicin will depend on when you join the study.
- One group will the study drug
- The other group will get a placebo (inactive substance that has no drug in it)
In addition to the study drug or placebo, you will also take either a drug called envafolimab or a combination of envafolimab and doxorubicin. Whether or not you take envafolimab alone or in combination with doxorubicin will depend on when you join the study.
Who Can Participate?
Eligibility
Adults 18+ who are diagnosed with dedifferentiated liposarcoma that has grown or has spread.
For more information on who can participate in this study please contact the study team at 919-681-4768.
For more information on who can participate in this study please contact the study team at 919-681-4768.
What is Involved?
We are doing this study to find out if a study drug called abemaciclib is a safe and effective option for patients with dedifferentiated liposarcoma that has grown or has spread.
Study Details
Principal Investigator
Richard
Riedel
Protocol Number
PRO00108915
NCT ID
NCT04967521
Phase
III
Enrollment Status
OPEN TO ACCRUAL